This protocol covers adult patients with vaginal cancer presenting at stage T2, T3, or T4 with node-negative disease (N0M0), or with any tumour stage accompanied by regional lymph node involvement (N1M0) — the locally advanced and node-positive presentations.
Adult patients with vaginal cancer whose disease has extended beyond early-stage localised disease — specifically T2, T3, or T4 tumours with no distant spread (N0M0), or any T-stage with regional nodal involvement (N1M0). This population requires a structured multimodal treatment approach.
Definitive platinum-based chemoradiotherapy consolidated by a brachytherapy boost is the preferred approach for this population — the complete regimen, sequencing, individual eligibility considerations, and contingency pathways are detailed in the full protocol.
DOI: 10.1016/j.radonc.2023.109662
Definitive platinum-based chemoradiotherapy consolidated by a brachytherapy boost is the preferred treatment of choice for the management of patients with locally advanced or node positive vaginal cancer.
View source ↗